2023-04-13 12:04:53 ET
- Lantern Pharma ( NASDAQ: LTRN ) said the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for an application related to its blood cancer drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea).
- The U.S. patent application no. 17/192,838 titled 'Illudin Analogs, Uses Thereof, and Methods for Synthesizing the same' covers the molecule LP-284, including claims covering the new molecular entity itself, according to the company.
- "LP-284 is an exciting new molecule for non-Hodgkin’s lymphomas and perhaps other hematological malignancies that we developed from initial AI insights from our RADR platform to a first-in-human clinical Phase 1 trial, which we are planning to launch later this year, in around two years and at significantly reduced costs," said Lantern's CEO and President Panna Sharma.
- Lantern expects the resulting LP-284 patent will expire in early 2039.
- The company expects to file an application to the U.S. FDA in mid-2023 for starting a phase 1 trial of LP-284 in B-cell non-Hodgkin’s lymphomas.
For further details see:
Lantern Pharma to get US patent linked to potential blood cancer drug LP-284